The Garden of Antimicrobial Delights

By Julian Davies The Garden of Antimicrobial Delights Major advances in genomics, cloning, and chemistry will restock the dwindling supply of effective antibiotics, but we can’t depend on big pharma and biotech. Green mold hyphae and fruiting structure, Aspergillus ustus. Dennis Kunkel Microscopy, Inc. / Visuals Unlimited, Inc. Almost all papers and reviews dealing with infectious diseases stress that new classes of antibiotic

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Almost all papers and reviews dealing with infectious diseases stress that new classes of antibiotics are badly needed to treat the increasing number of common and emerging cases of infection due to antibiotic-resistant organisms, be they bacteria, viruses, or parasites. What happened to the optimism of the late 1960s when the then Surgeon General of the United States announced “we can close the book on infectious diseases”? For some years now it has been clear that the situation with respect to the treatment of common bacterial infections, especially in hospitals, is poor, if not dire.1 Physicians have a diminishing armamentarium of antibiotics available for clinical use; most of the older compounds are ineffective against present-day resistant strains, and reinforcements are few and far between. The few novel compounds available are reserved for last-resort use and only in critical care units of hospitals.

If we are to continue with the current ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Julian Davies

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide